Urelumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Urelumab" in English language version.

refsWebsite

Global rank English rank

14nih.gov

4^th place

9doi.org

2^nd place

5semanticscholar.org

11^th place

8^th place

2harvard.edu

18^th place

17^th place

1creativebiolabs.net

low place

1cancer.gov

1,684^th place

1,350^th place

1crescendobiologics.com

low place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1handle.net

102^nd place

76^th place

1bmj.com

1,226^th place

1,421^st place

bmj.com

jitc.bmj.com

Zhang H, He D, Zhang M, Feng X, An A, Ju C, Li H, Ouyang D (November 2020). "Evaluation of efficacy and toxicity of CD137 immunotherapy with urelumab-mIgG1 chimeric antibody in CD137 HuGEMM™". Journal for Immunotherapy of Cancer. 8 (Suppl 3): A388. doi:10.1136/jitc-2020-SITC2020.0647. S2CID 228992726.

cancer.gov

"Urelumab". National Cancer Institute.

clinicaltrials.gov

Clinical trial number NCT00309023 for "Study of BMS-663513 in Patients With Advanced Cancer" at ClinicalTrials.gov

creativebiolabs.net

"Urelumab Overview".

crescendobiologics.com

Hashimoto K (May 2021). "CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development" (PDF). Cancers. 13 (10): 2288. doi:10.3390/cancers13102288. PMC 8150789. PMID 34064598.

doi.org

Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, et al. (May 2020). "Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma". American Journal of Hematology. 95 (5): 510–520. doi:10.1002/ajh.25757. PMC 7383599. PMID 32052473.
Ho SK, Xu Z, Thakur A, Fox M, Tan SS, DiGiammarino E, et al. (April 2020). "Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity". Molecular Cancer Therapeutics. 19 (4): 1040–1051. doi:10.1158/1535-7163.MCT-19-0608. PMID 31974274. S2CID 210882192.
Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X (May 2019). "Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity". Nature Communications. 10 (1): 2141. Bibcode:2019NatCo..10.2141Q. doi:10.1038/s41467-019-10088-1. PMC 6526162. PMID 31105267. S2CID 256641802.
Etxeberria I, Bolaños E, Teijeira A, Garasa S, Yanguas A, Azpilikueta A, et al. (June 2021). "Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic". Proceedings of the National Academy of Sciences of the United States of America. 118 (26). Bibcode:2021PNAS..11825930E. doi:10.1073/pnas.2025930118. PMC 8255787. PMID 34172583.
Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE (July 2015). "Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy". Clinical Cancer Research. 21 (14): 3113–3120. doi:10.1158/1078-0432.CCR-15-0263. PMC 5422104. PMID 25908780.
Hashimoto K (May 2021). "CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development" (PDF). Cancers. 13 (10): 2288. doi:10.3390/cancers13102288. PMC 8150789. PMID 34064598.
Cheng LS, Cheng YF, Liu WT, Shen A, Zhang D, Xu T, et al. (September 2022). "A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity". Journal of Translational Medicine. 20 (1): 415. doi:10.1186/s12967-022-03619-w. PMC 9461191. PMID 36076251. S2CID 255963562.
Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, et al. (April 2017). "Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody". Clinical Cancer Research. 23 (8): 1929–1936. doi:10.1158/1078-0432.CCR-16-1272. hdl:1805/14978. PMID 27756788. S2CID 19275490.
Zhang H, He D, Zhang M, Feng X, An A, Ju C, Li H, Ouyang D (November 2020). "Evaluation of efficacy and toxicity of CD137 immunotherapy with urelumab-mIgG1 chimeric antibody in CD137 HuGEMM™". Journal for Immunotherapy of Cancer. 8 (Suppl 3): A388. doi:10.1136/jitc-2020-SITC2020.0647. S2CID 228992726.

handle.net

hdl.handle.net

Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, et al. (April 2017). "Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody". Clinical Cancer Research. 23 (8): 1929–1936. doi:10.1158/1078-0432.CCR-16-1272. hdl:1805/14978. PMID 27756788. S2CID 19275490.

harvard.edu

ui.adsabs.harvard.edu

Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X (May 2019). "Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity". Nature Communications. 10 (1): 2141. Bibcode:2019NatCo..10.2141Q. doi:10.1038/s41467-019-10088-1. PMC 6526162. PMID 31105267. S2CID 256641802.
Etxeberria I, Bolaños E, Teijeira A, Garasa S, Yanguas A, Azpilikueta A, et al. (June 2021). "Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic". Proceedings of the National Academy of Sciences of the United States of America. 118 (26). Bibcode:2021PNAS..11825930E. doi:10.1073/pnas.2025930118. PMC 8255787. PMID 34172583.

nih.gov

pubmed.ncbi.nlm.nih.gov

Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, et al. (May 2020). "Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma". American Journal of Hematology. 95 (5): 510–520. doi:10.1002/ajh.25757. PMC 7383599. PMID 32052473.
Ho SK, Xu Z, Thakur A, Fox M, Tan SS, DiGiammarino E, et al. (April 2020). "Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity". Molecular Cancer Therapeutics. 19 (4): 1040–1051. doi:10.1158/1535-7163.MCT-19-0608. PMID 31974274. S2CID 210882192.
Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X (May 2019). "Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity". Nature Communications. 10 (1): 2141. Bibcode:2019NatCo..10.2141Q. doi:10.1038/s41467-019-10088-1. PMC 6526162. PMID 31105267. S2CID 256641802.
Etxeberria I, Bolaños E, Teijeira A, Garasa S, Yanguas A, Azpilikueta A, et al. (June 2021). "Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic". Proceedings of the National Academy of Sciences of the United States of America. 118 (26). Bibcode:2021PNAS..11825930E. doi:10.1073/pnas.2025930118. PMC 8255787. PMID 34172583.
Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE (July 2015). "Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy". Clinical Cancer Research. 21 (14): 3113–3120. doi:10.1158/1078-0432.CCR-15-0263. PMC 5422104. PMID 25908780.
Hashimoto K (May 2021). "CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development" (PDF). Cancers. 13 (10): 2288. doi:10.3390/cancers13102288. PMC 8150789. PMID 34064598.
Cheng LS, Cheng YF, Liu WT, Shen A, Zhang D, Xu T, et al. (September 2022). "A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity". Journal of Translational Medicine. 20 (1): 415. doi:10.1186/s12967-022-03619-w. PMC 9461191. PMID 36076251. S2CID 255963562.
Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, et al. (April 2017). "Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody". Clinical Cancer Research. 23 (8): 1929–1936. doi:10.1158/1078-0432.CCR-16-1272. hdl:1805/14978. PMID 27756788. S2CID 19275490.

ncbi.nlm.nih.gov

Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, et al. (May 2020). "Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma". American Journal of Hematology. 95 (5): 510–520. doi:10.1002/ajh.25757. PMC 7383599. PMID 32052473.
Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X (May 2019). "Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity". Nature Communications. 10 (1): 2141. Bibcode:2019NatCo..10.2141Q. doi:10.1038/s41467-019-10088-1. PMC 6526162. PMID 31105267. S2CID 256641802.
Etxeberria I, Bolaños E, Teijeira A, Garasa S, Yanguas A, Azpilikueta A, et al. (June 2021). "Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic". Proceedings of the National Academy of Sciences of the United States of America. 118 (26). Bibcode:2021PNAS..11825930E. doi:10.1073/pnas.2025930118. PMC 8255787. PMID 34172583.
Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE (July 2015). "Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy". Clinical Cancer Research. 21 (14): 3113–3120. doi:10.1158/1078-0432.CCR-15-0263. PMC 5422104. PMID 25908780.
Hashimoto K (May 2021). "CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development" (PDF). Cancers. 13 (10): 2288. doi:10.3390/cancers13102288. PMC 8150789. PMID 34064598.
Cheng LS, Cheng YF, Liu WT, Shen A, Zhang D, Xu T, et al. (September 2022). "A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity". Journal of Translational Medicine. 20 (1): 415. doi:10.1186/s12967-022-03619-w. PMC 9461191. PMID 36076251. S2CID 255963562.

semanticscholar.org

api.semanticscholar.org

Ho SK, Xu Z, Thakur A, Fox M, Tan SS, DiGiammarino E, et al. (April 2020). "Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity". Molecular Cancer Therapeutics. 19 (4): 1040–1051. doi:10.1158/1535-7163.MCT-19-0608. PMID 31974274. S2CID 210882192.
Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X (May 2019). "Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity". Nature Communications. 10 (1): 2141. Bibcode:2019NatCo..10.2141Q. doi:10.1038/s41467-019-10088-1. PMC 6526162. PMID 31105267. S2CID 256641802.
Cheng LS, Cheng YF, Liu WT, Shen A, Zhang D, Xu T, et al. (September 2022). "A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity". Journal of Translational Medicine. 20 (1): 415. doi:10.1186/s12967-022-03619-w. PMC 9461191. PMID 36076251. S2CID 255963562.
Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, et al. (April 2017). "Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody". Clinical Cancer Research. 23 (8): 1929–1936. doi:10.1158/1078-0432.CCR-16-1272. hdl:1805/14978. PMID 27756788. S2CID 19275490.
Zhang H, He D, Zhang M, Feng X, An A, Ju C, Li H, Ouyang D (November 2020). "Evaluation of efficacy and toxicity of CD137 immunotherapy with urelumab-mIgG1 chimeric antibody in CD137 HuGEMM™". Journal for Immunotherapy of Cancer. 8 (Suppl 3): A388. doi:10.1136/jitc-2020-SITC2020.0647. S2CID 228992726.